Analysis of approaches to pharmacotherapy of patients with cardiovascular diseases according to the data of the Ukrainian and British Formularies
Keywords:pharmacotherapy, cardiovascular diseases, formulary system, reimbursation, social health insurance
Aim. To analyze the approaches to pharmacotherapy of patients with cardiovascular diseases (CVD) indicated in the State Formulary of Medicines of Ukraine (SFMU) and the British National Formulary (BNF), as well as the reimbursement systems of drug cost in Ukraine and Great Britain. Materials and methods. In the course of the study materials from the on-line version of BNF No. 70 2015 and materials of SFMU No. 9 of 2017; official sites of the Ministry of Health of Ukraine and the National Health Service of Great Britain (NHS) were used. The methods of system analysis, logical generalization of information and the analytical method were also chosen. Results and discussion. A rapid growth of diseases of the cardiovascular system requires introduction of more effective, safe and affordable pharmacotherapy, which, in turn, can not be carried out without the availability of formularies of drugs and the formulary system as a whole. Approaches to pharmacotherapy of CVD patients indicated in SFMU and BNF, as well as the reimbursement systems of drug cost in Ukraine and Great Britain under conditions of social health insurance (SHI) have been analyzed. Conclusions. It has been found that not all drugs recommended for the treatment of CVD used in the UK are registered in the territory of Ukraine; moreover, most of the registered drugs do not have the appropriate dosing. Due to the limited number of drugs included in the reimbursement system the costs of therapy are incumbent upon the patient himself/herself in Ukraine, while in Britain with its SHI system a significant number of drugs under insurance prescriptions is compensable. Therefore, one of the ways to increase the availability of pharmacotherapy in Ukraine is development of the concept of the rational use of drugs and implementation of SHI.
Yevropeiska baza danykh statystychnoi informatsii “Zdorovia dlia vsikh”. Available at: http://medstat.gov.ua/ukr/normdoc.html
Online version: “British National Formulary № 70”. Available at: https://www.pharm.reviews/images/statyi/british–national–formulary–
Informatsiino–poshukova systema «Elektronnyi formuliar» 9 vypusk. Available at: http://www.dec.gov.ua/index.php/ua/informatsijno–
Official site “The National Institutefor Health and Care Excellence”. Available at: https://www.nice.org.uk/
Reiestr medyko–tekhnolohichnykh dokumentiv “Kardiolohiia”. Available at: http://mtd.dec.gov.ua/index.php/uk/reiestr–mtd/itemlist/
Ofitsiinyi sait Verkhovnoi Rady Ukrainy. Available at: http://w1.c1.rada.gov.ua/pls/zweb2/webproc4_1?pf3511=59745
Reiestr likarskykh zasobiv, vartist yakykh pidliahaie vidshkoduvanniu. Available at: http://www.apteka.ua/article/420532
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).